Trade

with

Biocryst Pharmaceuticals Inc
(NASDAQ: BCRX)
AdChoices
11.83
-0.36
-2.95%
After Hours :
11.80
-0.03
-0.25%

Open

12.30

Previous Close

12.19

Volume (Avg)

1.27M (1.42M)

Day's Range

11.83-12.69

52Wk Range

4.55-14.62

Market Cap.

848.88M

Dividend Rate ( Yield )

-

Beta

2.14

Shares Outstanding

71.76M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 17.33M

    • Net Income

    • -30.11M

    • Market Cap.

    • 848.88M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -213.74

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.14

    • Forward P/E

    • -42.74

    • Price/Sales

    • 39.68

    • Price/Book Value

    • 9.43

    • Price/Cash flow

    • -23.92

      • EBITDA

      • -25.03M

      • Return on Capital %

      • -42.02

      • Return on Equity %

      • -94.31

      • Return on Assets %

      • -42.02

      • Book Value/Share

      • 1.26

      • Shares Outstanding

      • 71.76M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 22.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.28

        • Cashflow Estimate

        • -0.57

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 78.60

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -21.07

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 99.47

            • 82.75

            • Pre-Tax Margin

            • -213.74

            • 39.38

            • Net Profit Margin

            • -213.74

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 98.50

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -136.90

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.08

              • 2.92

              • Quick Ratio

              • 2.96

              • 2.35

              • Interest Coverage

              • -6.80

              • 38.02

              • Leverage Ratio

              • 1.58

              • 2.21

              • Book Value/Share

              • 1.26

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -17.83

                • 217.39

                • P/E Ratio 5-Year High

                • -22.91

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.69

                • 124.82

                • Price/Sales Ratio

                • 38.02

                • 9.52

                • Price/Book Value

                • 9.06

                • 8.61

                • Price/Cash Flow Ratio

                • -23.92

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -94.31

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -42.02

                        (-42.20)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -38.96

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.20

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -30.72M
                      Operating Margin
                      -177.24
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -23.92
                      Ownership

                      Institutional Ownership

                      75.48%

                      Top 10 Institutions

                      61.44%

                      Mutual Fund Ownership

                      33.96%

                      Float

                      86.65%

                      5% / Insider Ownership

                      5.64%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® OTC Portfolio

                      •  

                        1,582,464

                      • 0.00

                      • 2.21

                      • Fidelity® Select Health Care Portfolio

                      •  

                        1,400,000

                      • 0.00

                      • 1.95

                      • SPDR® S&P Biotech ETF

                      •  

                        1,312,310

                      • -1.93

                      • 2.28

                      • Fidelity® Independence Fund

                      •  

                        1,311,590

                      • 0.00

                      • 1.83

                      • Fidelity® Advisor Small Cap Opps Fund

                      •  

                        1,289,050

                      • 29.03

                      • 1.80

                      • iShares Russell 2000 (AU)

                      •  

                        1,043,203

                      • -1.46

                      • 1.81

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,029,012

                      • 0.00

                      • 1.43

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        965,000

                      • 0.00

                      • 1.34

                      • iShares Nasdaq Biotechnology

                      •  

                        928,344

                      • -0.47

                      • 1.61

                      • Fidelity® Blue Chip Growth Fund

                      •  

                        833,700

                      • 0.00

                      • 1.16

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Baker Bros Advisors LLC

                      •  

                        10,890,872

                      • +85.63%

                      • 15.19

                      • Fidelity Management and Research Company

                      •  

                        10,613,025

                      • +18.23%

                      • 14.80

                      • Wellington Management Company, LLP

                      •  

                        5,349,345

                      • +33.08%

                      • 7.46

                      • RA Capital Management, LLC

                      •  

                        3,198,529

                      • -26.43%

                      • 4.46

                      • BlackRock Fund Advisors

                      •  

                        2,558,112

                      • +184.83%

                      • 3.57

                      • RTW INVESTMENTS, LLC

                      •  

                        2,460,865

                      • -9.82%

                      • 4.16

                      • D. E. Shaw & Co LP

                      •  

                        2,422,218

                      • +17.07%

                      • 3.38

                      • State Street Corp

                      •  

                        2,247,454

                      • +37.17%

                      • 3.13

                      • Vanguard Group, Inc.

                      •  

                        2,049,252

                      • +14.83%

                      • 2.86

                      • VHCP Management, LLC

                      •  

                        1,744,356

                      • 0.00%

                      • 2.43

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Core

                      Biocryst Pharmaceuticals Inc. is a Delaware corporation originally founded in 1986. The Company is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. It...more integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. It uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include Peramivir, BCX4161, Two 2nd generation HAE compounds, BCX4430, Forodesine and Ulodesine. Peramiv...moreir is a neuraminidase inhibitor for the treatment of patients with influenza and a potent, intravenously administered antiviral agent that rapidly delivers high plasma concentrations to the sites of infection. BCX4161 is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered treatment for the prevention of attacks in patients with Hereditary Angioedema. Forodesine is a PNP inhibitor in development as a treatment for cancer. Ulodesine is a PNP inhibitor developed as a once-daily oral, chronic treatment for gout. The Company’s product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.lessless

                      Key People

                      Jon P. Stonehouse

                      CEO/Director/President

                      Mr. George B. Abercrombie

                      Chairman of the Board/Director

                      Thomas R. Staab,II

                      CFO/Chief Accounting Officer/Senior VP/Treasurer

                      Ms. Alane Barnes

                      General Counsel/Secretary/Vice President

                      Stanley C. Erck

                      Director

                      • Biocryst Pharmaceuticals Inc

                      • 4505 Emperor Boulevard

                      • Durham, NC 27703

                      • USA.Map

                      • Phone: +1 919 859-1302

                      • Fax: +1 919 859-1314

                      • biocryst.com

                      Incorporated

                      1986

                      Employees

                      40

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: